Aramco-backed VC fund Wa’ed Ventures led a USD 10 mn pre-Series A funding round for US biotechnology firm Kure Cells, with participation from the Saudi healthcare firm Qomel, US pharma company NantBio, and US93, according to a pressrelease published on Thursday.

(** Tap or click the headline above to read this story with all of the links to our background and outside sources.)

Where will the money go? Kure Cells will allocate the fresh funds to expand its footprint in the Kingdom via upscaling its local team in R&D and manufacturing, with a focus on advanced cell therapy development. The US firm will work with Saudi researchers and clinicians to adapt its proprietary rapid-manufacturing platform to local regulatory and clinical environments.

About Kure Cells: The US company develops a rapid-manufacturing platform for CAR-T therapies, an advanced cancer treatment that modifies immune cells to recognize and destroy cancer cells, and other cell-based oncology therapies.

Tags: